| dc.description.abstract | Essential medicines are critical for health care services, including diagnosis,
prevention, treatment, and rehabilitation. By 2023, Indonesia's Primary Health
Center Facilities (PHCFs) and hospitals must ensure at least 80% supply as a
necessity. This study aims to assess the availability, price, and affordability of
essential medicines in PHCFs and hospitals in Gunungsitoli City. Samples were
collected sequentially, both retrospectively and prospectively. Secondary data
reviews were used to examine retrospective data, while interviews and observations
were used to collect prospective data. The results indicate that retinol and ranitidine
injections were not accessible in Gunungsitoli PHCFs, from 40 list of essential
medications most of it had a 100% availability rate. Retinol and ranitidine were
unavailable (0%) in PHCFs. Albendazol, DHP OAT and Retinol were unavailable
(0%) in Public Health, while diphenhydramine injection,ORS, Eye Ointment and
ciprofloxacin were only accessible at Private Hospital (50%). Affordability
research showed that medicines in certain PHCFs were still within an affordable
range for most patients (< IDR 93,633/day). Medicines provided in Public Hospital
were reasonably priced, while those in Private Hospital were varied from fare to
expensive. Medicine Price Ratio (MPR) indicated low-cost medicines in PHCFs,
low-to-moderate charges in Public Hospital, and numerous high-cost medicines in
Private Hospital. The study concludes that better essential medicine management is
needed to ensure constant availability and affordability in health care institutions. | en_US |
